Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
Adaptive Biotechnologies Corporation (ADPT)
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adhc.com
Company Research
Source: GlobeNewswire
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostics Services Program (MolDX), has expanded coverage of clonoSEQ® to include detection and monitoring of measurable residual disease (MRD) in Medicare patients with mantle cell lymphoma (MCL). MCL is a sub-type of non-Hodgkin lymphoma (NHL) with an annual incidence of approximately 4,000 cases per year in the United States.1 It is an aggressive disease, and most patients will relapse repeatedly; so
Show less
Read more
Impact Snapshot
Event Time:
ADPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADPT alerts
High impacting Adaptive Biotechnologies Corporation news events
Weekly update
A roundup of the hottest topics
ADPT
News
- Adaptive Biotechnologies Co. (NASDAQ: ADPT) had its price target raised by analysts at Piper Sandler from $6.00 to $7.00. They now have an "overweight" rating on the stock.MarketBeat
- Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
- Adaptive Biotechnologies Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Earnings To Watch: Adaptive Biotechnologies Corp (ADPT) Reports Q3 2024 Result [Yahoo! Finance]Yahoo! Finance
- Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024GlobeNewswire
ADPT
Earnings
- 11/7/24 - Beat
ADPT
Analyst Actions
- 10/2/24 - BTIG
ADPT
Sec Filings
- 11/19/24 - Form 4
- 11/13/24 - Form SC
- 11/13/24 - Form SC
- ADPT's page on the SEC website